BioXcel Turns To Commercialization With Positive Phase III Data In Agitation
Executive Summary
The company is developing a sublingual thin film of dexmedetomidine that could be used to treat agitation in a wide range of indications after planned initial launches in schizophrenia and bipolar disorder.
You may also be interested in...
BioXcel Gets First Approval With Igalmi For Neuropsychiatric Agitation
Sublingual film product Igalmi is approved to treat agitation related to schizophrenia and bipolar disorder, but BioXcel also is targeting a bigger market opportunity in Alzheimer’s dementia.
Finance Watch: Five Biopharma IPOs Bring US Total To 60 In 2021
Public Company Edition: Almost halfway through the year, initial public offerings equal nearly three-quarters of the 2020 total. Also, Pardes is one of four new SPAC mergers; HUTCHMED launched an IPO in Hong Kong; and Zentalis, Theravance and BioXcel launched follow-on offerings.
BioXcel's BXCL501 Data In Dementia Patients Reinforce Its Efficacy In Agitation
Execs said data from the institutional setting could be a bridge to other settings, while the duration of response indicates a real-world benefit that could aid adoption.